Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 7Lymphoid 6Plasma cell 1Myeloid 1Head & Neck 1

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 261fludarabine phosphate 233Azacitidine 182fludarabine 181Busulfan 176Cytarabine 155Imatinib Mesylate 152Mycophenolic Acid 148Tacrolimus 146Whole-Body Irradiation 142Peripheral Blood Stem Cell Transplantation 140Cyclosporine 110Antilymphocyte Serum 108Melphalan 107Methotrexate 105Filgrastim 101Decitabine 98nilotinib 94venetoclax 79ruxolitinib 79Dasatinib 68Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 63Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Medrol Veriderm × Myeloid × Clear all
NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡